Eculizumab: A Guide to its Use in Paroxysmal Nocturnal Hemoglobinuria

被引：8
|
作者：
Keating, Gillian M. [1 ]
Lyseng-Williamson, Katherine A. [1 ]
McKeage, Kate [1 ]
机构：
[1] Adis Int Ltd, Auckland 10, New Zealand
来源：
BIODRUGS | 2012年 / 26卷 / 02期
关键词：
COMPLEMENT INHIBITOR ECULIZUMAB;
D O I：
10.2165/11208420-000000000-00000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The targeted terminal complement inhibitor eculizumab (Soliris (R)) reduces intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as stabilizing hemoglobin levels, improving fatigue and health-related quality of life, and reducing the requirement for packed red cell transfusions. Eculizumab is generally well tolerated in patients with PNH, although the risk of Neisseria meningitidis infection is increased with eculizumab, meaning that patients must be vaccinated.
引用
收藏
页码：125 / 130
页数：6
相关论文
共 50 条
  • [21] Paroxysmal Nocturnal Hemoglobinuria and Thrombosis Before and After Eculizumab
    Munoz-Linares, Cristina
    Pastrana, Miguel
    Ojeda, Emilio
    Fores, Rafael
    Cabero, Martin
    Morillo, Daniel
    Bautista, Guiomar
    Navarro, Belen
    Krsnik, Isabel
    Gil, Santiago
    Regidor, Carmen
    de Lalglesia, Almudena
    Bueno, Jose Luis
    Garcia-Marco, Jose A.
    Cabrera, Jose Rafael
    [J]. BLOOD, 2013, 122 (21)
  • [22] Survival benefit of eculizumab in patients with paroxysmal nocturnal hemoglobinuria
    Patel, Ami
    Metzger, Jesse
    Terriou, Louis
    Patriquin, Christopher
    Griffin, Morag
    Lee, Jong Wook
    Gustovic, Phillippe
    Jiang, Wei
    Szer, Jeff
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 264 - 265
  • [23] The Importance of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: A Cohort Study
    Yenerel, Mustafa Nuri
    Erdem, Simge
    Mastanzade, Metban
    Nalcaci, Meliha
    [J]. BLOOD, 2018, 132
  • [24] Eculizumab A Review of its Use in Paroxysmal Nocturnal Haemoglobinuria
    McKeage, Kate
    [J]. DRUGS, 2011, 71 (17) : 2327 - 2345
  • [25] Ravulizumab in paroxysmal nocturnal hemoglobinuria: a profile of its use
    Kate McKeage
    Katherine Ann Lyseng-Williamson
    [J]. Drugs & Therapy Perspectives, 2019, 35 : 405 - 412
  • [26] Ravulizumab in paroxysmal nocturnal hemoglobinuria: a profile of its use
    McKeage, Kate
    Lyseng-Williamson, Katherine Ann
    [J]. DRUGS & THERAPY PERSPECTIVES, 2019, 35 (09) : 405 - 412
  • [27] Vaccination of patients with paroxysmal nocturnal hemoglobinuria under eculizumab treatment
    Rodriguez-Garcia, Juan
    Fernandez-Santos, Rafael
    Antonio Garcia-Erce, Jose
    [J]. MEDICINA CLINICA, 2012, 138 (14): : 640 - 641
  • [28] Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria
    Schrezenmeier, Hubert
    Hoechsmann, Britta
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2009, 2 (01) : 7 - 16
  • [29] Treatment of paroxysmal nocturnal hemoglobinuria in pregnancy with eculizumab: A case report
    Fassett, Michael J.
    Lopez, Adrian L. Hernandez
    [J]. CASE REPORTS IN WOMENS HEALTH, 2021, 30
  • [30] POSITIVE OUTCOMES OF THROMBOSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WITH ECULIZUMAB THERAPY
    Villegas, A.
    Urbano, A.
    Cuevas, M.
    Roncero, M.
    Ruiz, B.
    Cordoba, R.
    Fernandez, F.
    Toscano, R.
    Gaya, A.
    Bermejo, A.
    Mardones, L.
    Loureiro, C.
    Moreno, D.
    Alcala, A.
    De La Iglesia, S.
    Calvillo, M.
    Menayo, M.
    Gonzalez, A.
    Arrizabalaga, B.
    [J]. HAEMATOLOGICA, 2013, 98 : 579 - 579
12345